Last reviewed · How we verify
Benzimidazole Anthelmintic
Benzimidazole Anthelmintic, marketed by Centre de Recherche Médicale de Lambaréné, holds a position in the anthelmintic market with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and mechanism of action, which is well-documented and effective against parasitic infections. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Benzimidazole Anthelmintic |
|---|---|
| Also known as | Albendazole, Mebendazole, Pyrantel |
| Sponsor | Centre de Recherche Médicale de Lambaréné |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC (PHASE2)
- Efficacy and Safety of Moxidectin-Albendazole Co-administration in SAC (PHASE3)
- A Safety and Efficacy Study of Different Doses of Oxfendazole Compared to a Single Dose of Albendazole to Treat Trichuris Trichiura Infection in Adults (PHASE2)
- Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration (PHASE2, PHASE3)
- Efficacy and Safety of MOX/ALB Co-administration (PHASE3)
- Monitoring Drug Efficacy and Anthelmintic Resistance in Soil-transmitted Helminth Programs
- RDD1609 as a Treatment for Idiopathic Pruritus Ani (PHASE2)
- Human Soil Transmitted Helminths (STH) Resistance to Benzimidazole in School Aged Children Living in Gabon (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Benzimidazole Anthelmintic CI brief — competitive landscape report
- Benzimidazole Anthelmintic updates RSS · CI watch RSS
- Centre de Recherche Médicale de Lambaréné portfolio CI